Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3658_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •2 Principles of radiofrequency and microwave tumor ablation
- •Cooling in microwave ablation
- •Pulsed RF application
- •Operator and technique
- •Choice of applicator
- •Overlapping techniques
- •Introduction
- •Biology of heating
- •Radiofrequency ablation
- •Microwave ablation
- •Energy-deposited technology
- •Multitine applicators
- •Internally cooled electrodes
- •Perfused electrodes
- •Ancillary procedures
- •Combination therapies
- •Combining RF with transarterial chemoembolization
- •Combining RF with chemotherapy
- •Combining RF ablation with radiation
- •Patient selection
- •Conclusion
- •References
- •3 Principles of irreversible electroporation
- •Introduction
- •Numerical simulations
- •Clinical considerations
- •Clinical experience
- •Conclusion
- •References
- •4 Principles of high-intensity focused ultrasound
- •Introduction
- •History
- •Ablation
- •Hyperthermia
- •Thermal dose concept
- •Cavitation
- •Histotripsy
- •Microstreaming
- •HIFU system technology
- •Ultrasound guidance
- •MRI guidance
- •HIFU devices
- •Clinical applications
- •Prostate
- •Breast
- •Liver
- •Bone
- •Emerging applications
- •Targeted drug delivery
- •Blood–brain barrier disruption
- •Conclusion
- •References
- •5 Principles of tumor embolotherapy and chemoembolization
- •Tumor embolotherapy
- •General indications
- •Embolic materials
- •Gelfoam
- •Coils
- •Absolute ethanol
- •Microspheres
- •Pre-embolization evaluation
- •Roadmap and superselective arteriography
- •Chemoembolization
- •Basic principle
- •Chemotherapeutic agents used for chemoembolization
- •Lipiodol chemoembolization
- •Subsegmental chemoembolization
- •Drug-eluting bead TACE (DEB-TACE)
- •References
- •6 Principles of radioembolization
- •Introduction
- •Mechanism of radioembolization
- •Radioembolic material
- •Indications and contraindications
- •Imaging considerations
- •Base and follow-up cross-sectional imaging
- •Localization imaging (nuclear medicine imaging)
- •Determining treatment dosage (activity)
- •(Y-90) SIR-Sphere
- •(Y-90) TheraSphere
- •Microcatheters
- •(Y-90) SIR-Sphere
- •(Y-90) TheraSphere
- •Radiation safety considerations
- •Patient release
- •Radiation safety considerations for cases involving surgery
- •Radiation safety considerations in case of autopsy, burial, or cremation
- •References
- •Background
- •Regional delivery of the drug leads to increased local concentration
- •Increased local concentration leads to increased therapeutic response
- •Regional delivery of a drug leads to decreased systemic exposure
- •5-Fluorouracil
- •Irinotecan
- •Oxaliplatin
- •Hepatic artery combination chemotherapy administration
- •Hepatic intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI)
- •Therapeutic monoclonal antibodies
- •Future research
- •Regional therapy pharmacology appendix
- •Pharmacology appendix
- •References
- •Introduction
- •Imaging for procedure planning
- •Imaging for device delivery
- •Advances in real-time imaging
- •Three-dimensionality
- •Navigation
- •Robotics
- •Combining best systemic chemotherapy with best HAI strategy
- •Open access to the patient
- •Radiation exposure
- •Intraprocedural monitoring
- •Imaging for therapy assessment
- •Summary
- •References
- •9 Novel developments in MR assessment of treatment response after locoregional therapy
- •Anatomic biomarkers
- •The volumetric approach
- •Conclusion
- •References
- •10 Assessment and triage of hepatocellular carcinoma
- •Summary
- •Introduction
- •Assessment of hepatocellular carcinoma
- •Diagnostic criteria
- •Clinical staging
- •Triage of hepatocellular carcinoma
- •Liver transplantation
- •Surgical resection
- •Image-guided ablation
- •Transarterial treatment
- •Systemic treatment
- •Conclusion
- •References
- •11 Image-guided ablation of hepatocellular carcinoma
- •Introduction
- •Very-early-stage hepatocellular carcinoma
- •Early-stage hepatocellular carcinoma
- •Conclusion
- •References
- •Celiac trunk anatomy
- •Normal celiac trunk anatomy and variations
- •Celiac stenosis or occlusion
- •Hepatic artery anatomy
- •Intrahepatic variations in branching segmental hepatic arteries
- •Non-hepatic arteries arising from hepatic arteries
- •Pancreaticoduodenal arteries
- •Extrahepatic collateral arteries
- •Anatomy of extrahepatic collateral arteries
- •Inferior phrenic arteries
- •Internal mammary arteries
- •Intercostal and lumbar arteries
- •Omental arteries
- •Adrenal arteries
- •Renal and renal capsular arteries
- •Gastric arteries
- •Colic branches
- •Transcatheter management of extrahepatic collateral arteries
- •References
- •Background
- •Patient selection and contraindications for TACE and DEB-TACE
- •Technique
- •Follow-up and evaluation of response to treatment
- •Clinical outcome
- •Combination therapies
- •Conclusion and outlook
- •References
- •Patient selection
- •Technique
- •Dosimetry
- •Adverse events and toxicities
- •Clinical outcomes
- •References
- •15 Image-guided therapy of intrahepatic cholangiocarcinoma
- •Curative therapies
- •Percutaneous ablation
- •Non-curative therapies
- •Chemoembolization
- •Radioembolization
- •Multidisciplinary approach
- •References
- •Introduction
- •Indications
- •Contraindications
- •Ablation modalities
- •Radiofrequency ablation
- •Cryoablation
- •Microwave ablation
- •Irreversible electroporation
- •Laser-induced interstitial thermotherapy
- •Discussion
- •References
- •17 Assessment, triage, and chemoembolization for colorectal liver metastases
- •Assessment of the patient with liver metastases
- •Triage of patients with liver metastases
- •Resection
- •Ablation
- •Intra-arterial chemoinfusion
- •Systemic therapy
- •Chemoembolization
- •Patient selection for chemoembolization
- •Chemoembolization regimens
- •“Conventional” cocktails
- •Drug-eluting microsphere platforms
- •Technical aspects of chemoembolization
- •Loading
- •Technique for drug-eluting microsphere embolization
- •Delivery endpoints
- •Outcomes with drug-eluting microspheres
- •Summary
- •References
- •18 Radioembolization for colorectal liver metastases
- •Introduction
- •Patient presentation
- •Preimplantation workup procedure
- •Treatment process
- •Dosimetry and dose calculation
- •TheraSphere
- •SIR-Spheres
- •Postprocedural care and follow-up
- •Postprocedure considerations
- •Postembolization syndrome (20–30%)
- •CT/PET evaluation of tumor response
- •Radioembolization combined with second- or third-line chemotherapy
- •Conclusion
- •References
- •19 Assessment, triage, and liver-directed therapies for neuroendocrine tumor metastases
- •Terminology
- •Demographics and epidemiology
- •Diagnosis
- •Prognosis
- •Multidisciplinary triage of neuroendocrine neoplasms
- •Systemic therapies
- •Surgical management
- •Image-guided therapy
- •Tumor ablation
- •Hepatic arterial therapy
- •Conclusion
- •References
- •20 Preoperative portal vein embolization
- •Mechanisms of liver regeneration
- •Rate of liver regeneration
- •Standard approaches
- •Additional approaches
- •PVE in conjunction with transarterial therapies
- •Extent of embolization
- •Embolic materials
- •Complications
- •General indications
- •General contraindications
- •Underlying liver disease
- •High-dose chemotherapy
- •Conclusion
- •References
- •Photodynamic therapy
- •Radiotherapy
- •References
- •Clinical overview
- •Staging
- •Diagnosis
- •Treatment options
- •Surgery
- •Percutaneous techniques
- •Radiofrequency ablation
- •Background
- •Histology of RFA
- •Microwave ablation
- •Background
- •Histology
- •Cryoablation
- •Background
- •Histology of cryoablation
- •Indications for percutaneous ablation
- •Patient factors
- •Preablation imaging
- •Adjunctive procedures
- •Technique
- •Anesthesia
- •Modality for guidance
- •Radiofrequency ablation
- •Microwave ablation
- •Cryoablation
- •Adjacent structures
- •Postprocedure follow-up
- •Complications
- •Treatment of metastatic disease
- •Surgical and RFA options
- •Medical therapies
- •Conclusion
- •References
- •23 Embolotherapy in the management of renal cell carcinoma
- •Introduction
- •Basic concepts
- •Embolization technique
- •Preoperative embolization
- •Radical nephrectomy
- •Partial nephrectomy
- •Postoperative embolization
- •Palliative embolization
- •Complications
- •Conclusion
- •References
- •Physics of ablation therapy
- •Radiofrequency ablation
- •Microwave ablation
- •Cryoablation
- •Irreversible electroporation
- •Performing ablation therapy
- •Patient selection
- •Procedure
- •Radiofrequency ablation
- •Microwave ablation
- •Cryoablation
- •Irreversible electroporation
- •Imaging follow-up
- •Radiofrequency ablation
- •Microwave ablation
- •Cryoablation
- •Irreversible electroporation
- •Comparison of thermal ablation techniques
- •Applications and outcomes for thoracic ablation
- •Palliation
- •Conclusion
- •References
- •Introduction
- •Indications for treatment
- •Preprocedural imaging
- •Contraindications to ablation treatment
- •RFA technique
- •RFA pain palliation outcomes
- •Cryoablation technique
- •Cryoablation pain palliation outcomes
- •Emerging technologies
- •Summary
- •References
- •26 Cementoplasty and musculoskeletal interventions
- •Introduction
- •Indications
- •Contraindications
- •Technique
- •Postprocedural care and follow-up
- •Current bone cement properties and future directions
- •Percutaneous sacroplasty, osteoplasty, and advance hybrid stabilization techniques
- •Summary
- •References
- •27 Prostate ablations
- •Introduction
- •Patient selection
- •Cancer detection and treatment guidance
- •Patient selection
- •Targeting strategies
- •Image guidance for prostate ablation
- •Ultrasound guidance
- •MR guidance
- •Computed tomography guidance
- •Positron emission tomography guidance
- •Prostate ablation techniques
- •High-intensity focused ultrasound
- •Cryoablation
- •Other techniques
- •Postprocedure evaluation
- •Complications and outcomes
- •Local control
- •Conclusion
- •Acknowledgments
- •References
- •Indications
- •Rationale
- •Technique
- •Catheter positioning
- •Contraindications
- •Results
- •Port/catheter placement
- •Chemotherapy
- •Description
- •Indications
- •Preoperative assessment
- •Catheter tip location
- •Update on vein thrombosis prophylaxis and treatment
- •Catheter-related infection
- •References
- •29 Palliative care and symptom management
- •Palliative care and communication with cancer patients
- •Communication with cancer patients
- •Prognostication
- •Medical symptom management
- •Pain
- •Non-opioid analgesics
- •Opioid analgesics
- •Adjuvant analgesics
- •Bone metastases
- •Nausea and vomiting
- •Constipation
- •Constitutional symptoms
- •Ascites
- •Psychiatric symptoms
- •Depression
- •Anxiety
- •Summary
- •References
- •Introduction
- •Celiac plexus neurolysis
- •Anatomy
- •Technique
- •Positioning and approach
- •Antecrural
- •Retrocrural
- •Outcomes
- •Complications
- •Superior hypogastric neurolysis
- •Anatomy
- •Technique
- •Positioning and approach
- •Outcomes
- •Complications
- •Ganglion impar neurolysis
- •Anatomy
- •Technique
- •Outcomes
- •Complications
- •References
- •Introduction
- •Management of ascites
- •Diuretics and sodium restriction
- •Large-volume paracentesis
- •Permanent indwelling catheters
- •Pigtail or Cope-type loop catheter
- •PleurX and Asept catheters
- •Peritoneal Port-A-Catheters
- •Thoracentesis
- •Chest drainage catheters
- •Pigtail catheters
- •Tunneled catheters
- •Summary of recommendations and guidelines
- •References
- •Index

Chapter3:Irreversible electroporation
20. NealRE2nd,SinghR,HatcherHC,etal.Treatmentofbreast
cancerthroughtheapplicationofirreversibleelectroporation
usinganovelminimallyinvasivesingleneedleelectrode.Breast
Cancer Res Treat2010;123(1):295–301.
21. IvorraA,Al-SakereB,RubinskyB,etal.Invivoelectrical
conductivitymeasurementsduringandaertumor
electroporation:conductivitychangesreectthetreatment
outcome.Phys Med Biol2009;54(19):5949–5963.
22. NealRE2nd,GarciaPA,RobertsonJL,etal.Experimental
characterizationandnumericalmodelingoftissueelectrical
conductivityduringpulsedelectriceldsforirreversible
electroporationtreatmentplanning.IEEE Trans Biomed Eng
2012;59(4):1076–1085.
23. NealRE2nd,MillarJL,KavnoudiasH,etal.Invivo
characterizationandnumericalsimulationofprostate
propertiesfornon-thermalirreversibleelectroporationablation.
Prostate2014;74(5):458–468.
24. AuJT,KinghamTP,JunK,etal.Irreversibleelectroporation
ablationofthelivercanbedetectedwithultrasoundB-mode
andelastography.Surgery2013;153(6):787–793.
25. AppelbaumL,Ben-DavidE,SosnaJ,etal.USndingsaer
irreversibleelectroporationablation:radiologic–pathologic
correlation.Radiology2012;262(1):117–125.
26. HjoujM,LastD,GuezD,etal.MRIstudyonreversibleand
irreversibleelectroporationinducedbloodbrainbarrier
disruption.PLoS ONE2012;7(8):e42817.
27. WendlerJJ,PorschM,HühneS,etal.Short-andmid-term
eectsofirreversibleelectroporationonnormalrenal
tissue:ananimalmodel.Cardiovasc Intervent Radiol2013;36
(2):512–520.
28. ZhangY,WhiteSB,NicolaiJR,etal.Multimodalityimagingto
assessimmediateresponsetoirreversibleelectroporationina
ratlivertumormodel.Radiology2014;18:130989.
29. RyanER,SofocleousCT,SchöderH,etal.Split-dosetechnique
forFDGPET/CT-guidedpercutaneousablation:amethodto
facilitatelesiontargetingandtoprovideimmediateassessment
oftreatmenteectiveness.Radiology2013;268(1):288–295.
30. ScheerHJ,NielsenK,deJongMC,etal.Irreversible
electroporationfornonthermaltumorablationintheclinical
setting:asystematicreviewofsafetyandecacy.J Vasc Interv
Radiol2014;pii:S1051–0443(14)00101–8.
31. CannonR,EllisS,HayesD,etal.Safetyandearlyecacyof
irreversibleelectroporationforhepatictumorsinproximityto
vitalstructures.J Surg Oncol2013;107(5):544–549.
32. MartinRC2nd,McFarlandK,EllisS,etal.Irreversible
electroporationinlocallyadvancedpancreaticcancer:potential
improvedoverallsurvival.Ann Surg Oncol2013;20Suppl
3:S443–S449.
33. NarayananG,HoseinPJ,AroraG,etal.Percutaneous
irreversibleelectroporationfordownstagingandcontrolof
unresectablepancreaticadenocarcinoma.J Vasc Interv Radiol
2012;23(12):1613–1621.
19

Chapter
Principles of high-intensity focused ultrasound
4
Aradhana M. Venkatesan and Bradford J.Wood
Introduction
High-intensityfocusedultrasound(HIFU),alsoknownasfocused
ultrasound(US),isa non-invasiveimage-guidedtherapywhich
hasbeenprimarilyemployedintheclinicalrealmfornon-invasive
thermalablationofbenignandmalignantneoplasms.
imagingguidance,treatmentmonitoring,andtherapycontrolare
achievedwitheitherUS ormagnetic resonanceimaging(MRI)
guidance.3 HIFU clinical experience has been described in the
1,2
Real-time
treatment of leiomyomata (uterine broids), prostate (benign
prostatichypertrophyandcancer),breast,hepatic,renal,pancreatic,brain,andbonetumors,althoughformostofthesetumors,
relativelysmallnumbersoftreatedpatientshavebeendescribed
andwidespreadadoptionofHIFUthermoablationremainslimited.Ongoingtechnicalchallengesincludethefeasibilityoftreatinglargetumorswithinanite treatmenttime,treatingtumors
pronetomotion,andaccessingtargetswhentheacousticwindow
isrestrictedbyinterveninganatomy(e.g.,ribs,bowel).
ArangeofprovocativebioeectsoftherapeuticUSbeyond
thermoablationhavethepotentialtobeleveragedinthecareof
selectedoncologypatients.Hyperthermiceectscanpotentiate
therelease of thermosensitive drugs, enhance the permeabilityandretention(“EPReect”)ofchemotherapeuticagentsor
nanoparticles,sensitizetissuestoradiationeects,andpotentially augment therapeutic gene transfection within tumors.
MechanicaleectsofHIFU,includingstableandinertialcavitationandradiationforces,alsoplayrolesinheat-sensitivedrug
andgenedelivery,andtheenhancedpermeabilityoftherapeuticmolecules,anddisruptionoftheblood–brainbarrier(BBB).
eseareareasofongoingandpromisingoncologicresearch.
ischapterwillprovideanoverviewoftheprinciplesand
existingtherapeuticplatformsforHIFU,includingUSandMRI
guidance, treatment planning, and monitoring capabilities.
Asummaryofcurrentandpotentialfutureclinicalapplications
isalsopresented.
a focused US system and executed preclinical testing in the
brain.4Subsequently,inthe1950s,theFrybrothersdevelopeda
clinicalHIFUdeviceintendedtotreatpatientswithneurological disorders likeParkinson’s disease.5 is systememployed
radiography to determine target location in relation to the
overlyingcalvariumandfocusedtheUSbeam throughacraniotomy.
5–7
e needtoremoveaportionoftheskullandthe
absenceofhigh-resolutionneuroimaginglimitedfurtherdevelopmentofthisresearchatthattime.8Inthe1970s,theability
offocusedUStoinducehyperthermiaintissue(i.e.,elevation
oftissuetemperatureto43°C)wasoutlined.
8,9
Sincethe1990s,
coincidentwith the maturationof US transducerdesignsand
more precise intraprocedural targeting and monitoring with
diagnosticUSandMRI,scienticinterestinHIFUforoncologicapplicationshasbeenrevitalized.
8
Thermal eects
Ablation
e principles governing diagnostic US and HIFU are the
same. Representativetime-averaged intensities for diagnostic
US (B-mode, pulsed, or continuous Doppler) may be up to
720mW/cm2accordingtoUSFoodandDrugAdministration
(FDA)regulations.eintensityofHIFU,incontrast,isseveral
timeshigher,from100to10,000W/cm2,withpeakcompression
pressuresofupto70MPaandpeakrarefactionpressuresupto
20MPa.8HIFUablationutilizesapiezoelectrictransducerwith
acenterfrequencytypicallyof1–7MHzwhichisinsonatedinto
the body via acouplingmedia, such as a degassedwater–gel
pad interfaceforextracorporeal systems or with a gel-coated
water balloon surrounding the transducer for endocavitary
approaches.
HIFU-treatedtissuesexperiencearapidelevationoftemperatureas a resultof acoustic energyabsorption at the target focus.
1
1,8,10
e small volume heated rapidly results in a
well-demarcated focus of coagulativenecrosis, with the skin
HIFU principles and bioeects
History
HIFUisnotanewtechnology.Itsrstmedicallyapplicableuse
wasdescribed by Lynn et al. in 1942;these authorsdesigned
andadditionaloverlyingtissue layersbeing either unaected
or sustaining minimal temperatureelevation due to the low
acoustic energy away from the US focus
1,10
(Figures 4.1 and
4.2).Aswithotherformsofthermoablation,thedegreeofther-
maldamagetothetissuedependsonthetemperaturereached
andthedurationoftheexposure.6Tissuetemperatureelevated
Interventional Oncology, Second Edition, ed. Jean-François H.Geschwind and Michael C.Soulen. Published by Cambridge University Press.
©Cambridge University Press2016
20

Chapter4:High-intensity focused ultrasound
Figure 4.1 Intraprocedural magnetic resonance (MR)-guided high-intensity focused ultrasound (HIFU) monitoring and MR imaging and histopathologic findings
after leiomyoma ablation with MR-guided HIFU. Graphic user interface displays multiplanar three-dimensional T2-weighted imaging and overlaid temperature
maps (A, B) as well as overlaid thermal dose estimates (C, D) during sonication of an anterior intramural leiomyoma within the body of the uterus. Accumulated
thermal dose information in the treated volume is displayed at the end of each sonication as a thermal dose estimate. These thermal doses are reported in
CEM43, with 30 CEM43 (beige polygon, C, D) corresponding to onset of tissue alteration and 240 CEM43 (white polygon, C, D) representing predicted territory of
complete necrosis. Both 30 CEM43 and 240 CEM43 thermal dose estimates are updated after each sonication. Sagittal (E) and coronal (F) contrast-enhanced MR
images after HIFU show non-enhancing treated region (arrows). (G) Bivalved gross uterine specimen shows hemorrhagic necrosis in the area of treatment (arrows).
Low-magnification (4×) histologic images of margin (H), high-magnification (10×) images of margin (I), and high-magnification images of the center of the ablation
zone (J) confirm necrosis (asterisk) and narrow zone of transition (arrows) between viable and necrotic HIFU-treated tissue. (Reprinted as per Elsevier permissions
requirements from Venkatesan AM, Partanen A, Pulanic TK, et al. Magnetic resonance imaging-guided volumetric ablation of symptomatic leiomyomata: correlation
of imaging with histology. J Vasc Interv Radiol 2012; 23: 786–794.14)
tomorethan60°Cfor1secondwillgenerallyleadtoinstantaneousandirreversiblecelldeathviacoagulationnecrosis.8With
longerHIFUexposures,perfusionresultsinareductionofthe
temperaturegradientachieved. Tissues in proximity to large
bloodvesselsexperienceconvectiveheatlossanalogoustothat
encountered for other forms of thermoablation, particularly
iftheHIFU energy delivery islongorslow.6Blood ow and
perfusionvariabilitybaseduponanatomicsiteandtissuetype
remainachallengeforecaciousHIFUtherapy,asthesecanbe
associatedwithtreatmentinecienciesandvariabilityintreatment outcome.
6,11–14
In addition to controlling the temperatureachievedand exposure duration, US beam focusingcan
achievehigh acoustic intensities.
1,8
Averageablation volumes
achievablewith individualHIFUsonicationsareabout1 mm
indiameterandabout10mminlength,withanaveragevolumebetween50and300mm3.
1,8
Byperformingmultipleindividualshortexposures,larger
compositeablation volumes,whichencompassasolidtumor
andintendedtumor-freemargin,canbeachieved.1Pausesare
oen required between sonications to prevent tissue boiling
and bubble formation,which can reect and distort the US
eld,resultinginunpredictablelesiongrowthand non-target
thermal injury,or uncontrollable cavitation.1 To circumvent
thepotentialforlongtreatmenttimesassociatedwiththisstrategy,specictechniqueshavebeendeveloped,includingtheuse
ofinterleavemode,wherebysonicationorderisprescribedso
21

Section II:Principles of image-guided therapies
t Rt
t
0
=∆
−
Figure 4.2 Therapy planning for
magnetic resonance (MR)-guided
high-intensity focused ultrasound
leiomyoma ablation. Therapy-planning
software enables delineation of the
planned treatment volume (PTV) and
individual sonications during treatment
planning. Each sonication cell (either
treatment cell or feedback cell) may
be assigned its own acoustic power
setting, sonication frequency, and cell
diameter. (A) Individual sonications are
delineated, and cumulative volume of
individual planned sonications, known as
a treatment cluster, is compared with PTV
to determine the percentage of target
volume to be ablated (in this example,
28%). Regulatory stipulations for this
trial permitted ablation of 30% of target
fibroid volume. (B) Three-dimensional
T2-weighted MR imaging allows for
multiplanar assessment and treatment
planning, with PTV (red ellipse) and
After populating PTV with intended sonication cells, the radiologist verifies on all planes to confirm that cells remain within the PTV outline. (Reprinted as per
Elsevier permissions requirements from Venkatesan AM, Partanen A, Pulanic TK, et al. Magnetic resonance imaging-guided volumetric ablation of symptomatic
leiomyomata: correlation of imaging with histology. J Vasc Interv Radiol 2012; 23: 786–794.14)
planned sonications (green ellipses)
superpositioned on anatomic images.
astominimizesonicationoverlap,resultinginareductionin
cooling times.6 Another method to achieve conuent, more
time-ecientHIFUablationsemploysphased-arraytransducersandbeam-formingtechniqueswhichcanenlargetheeectiveUSfocalareawhilepreservingthefocusingcharacteristic
oftheUS eld.
1,15
Volumetric ablation,in particular,employs
phased-array transducers and driving electronics enabling
rapidtemporalswitchingofthefocalpointlocationwithinthe
treatedtissue.
12,14,16–19
Largertissuevolumesareheatedperunit
timeusingthistechnique,whichtakesadvantageoflocalheat
diusion.
1,12,14,16–19
Hyperthermia
ClinicallyrelevantthermaleectsoffocusedUSoccuratboth
ablative(>60°C)andnon-ablativehyperthermictemperatures
(typically40–45°C).Hyperthermiacansensitizetissuetoradiationorchemotherapyandthesearepotential emergingapplicationsforfocusedUS.
6,20,21
Activationof heat-sensitive genes
usingHIFUisalsobeinginvestigated,wherebyHIFU has the
potentialtoenablelocal, physical, andspatiotemporalcontrol
oftransgeneexpression.
6,20,22
Chemotherapeuticagentsencapsulatedwithin thermosensitive liposomesmayalso be locally
released within tumors using HIFU. Properties intrinsic to
heat-sensitive liposomes include: (1) their increased bilayer
permeabilityatagel-to-liquidcrystallinephasetransitiontemperaturecomparedwithboththe solidandliquidphases, and
(2)theabilityofawater-solublecomponenttobereleasedfrom
the bilayer as it begins to melt.23 In the hyperthermic range,
heat-sensitive liposomes undergo a phase transition, from a
solid-ordered to liquid-disordered phase, with resultantdrug
24,25
release.
Ultrasound eld generation and transducerdesign
HIFUtransducersvaryinsizedependingontheclinicalapplication,whichcanrangefromsupercialendocavitarytargetsto
deepabdominaltargetsthatnecessitategreateracousticpower
forsuccessfulablation.
3,26
esimplestHIFUtransducerstypically consist of a single-element spherical or at transducer
moved mechanically to ablate tissue using a point-by-point
(rastering)sonicationapproach.Mostcommonly,thesetransducersareself-focusingpiezoceramictransducerswithaxed
apertureandfocallength.1Morecomplexphased-arraytransducerscomprisemultipletransducerelements,witheach elementdrivenbyaseparateradiofrequencysignal withitsown
phase, frequency, and amplitude. As a result, selective activation of individual elements and electronic beam steering
of these transducers can be performed.1 For specic clinical
applications,such as brain HIFU,the number of elements in
phased-arraytransducerscan be in the thousands.
1,27
Topreventthermaldestructionofthetransducerduringhigh-power
applications,activewatercoolingmaybeutilized.Giventheir
morecomplexdesign,phased-arraytransducers are typically
muchmoreexpensivethansingle-elementdevices,1butmaybe
fasterandmoreversatileinapplications.
Thermal dose concept
Tissuethermaldamageathigh-temperatureHIFUexposures
can be predicted via an Arrhenius analysis or, more commonly, by using the Sapareto–Dewey thermal dose model,
tfinal
−
43
T
−
(
)
43
∑
lentminutesat43.0°C,Tisthemeantemperatureduringtime
Δt,andRisaconstantthatequals0.50above43.0°Cand0.25
below 43.0°C.28 e Sapareto–Dewey model describes tissue
thermaldamageasapproximatelylinearlydependentonexposure time and exponentially dependent on the temperature
elevation,withthethermaldoseexpressedinequivalentminutes at 43°C (EM43°C, CEM43°C, or t43).
of120–240 minutesat43°Cresultin irreversible coagulative
, where t43 is the thermal dose in equiva-
8,29
ermal doses
22

Chapter4:High-intensity focused ultrasound
necrosis, although the specic threshold for a given target
will varydepending on tissue type,regional blood ow,and
perfusion.
8,30
Mechanical eects
MechanicaleectsofHIFUaresustainedwhenacousticpulses
at high intensitiesare utilized.
includecavitation,microstreaming,andradiationforces.
Cavitation
Athigh-pressureUSamplitudes,microbubblesdevelopasfoci
ofgas are drawn out of solution on the basisof US-induced
local temperatureelevationsand alternating tissue compressionandrarefaction.
tion,growth,andimplosivecollapseofthesebubblesandtheir
interactionwithhigh-intensityUS.32Preformedmicrobubbles,
availableclinicallyasUScontrastagents,canbeusedascavitationsitesatlower-intensityUSexposures.
itationhave been described: stable and inertial cavitation.
Stable(non-inertial)cavitationrefers tothe stableoscillation
ofbubblesizewhenexposedtoalow-pressureacousticeld.8
Inertial(unstable)cavitationisassociatedwithviolentoscillationsofthebubble,rapidbubblegrowthduringtherarefaction
phase, and subsequentimplosivebubblecollapse, which can
resultincelldeathandtissuedamage.
HIFUmechanicaleects,usedin conjunctionwithHIFU
thermal ablation, may result in larger tumor ablation volumes and reduced treatmenttimes.6 Histologic studies have
also demonstrated disruption of the BBB, selective vascular
damage, arterial occlusion, and disruptionof atherosclerotic
plaquesandthrombiasaresultof cavitation.
canalsoaectcellmembraneandvascularpermeability,which
hasthepotentialtobeleveragedfortargeteddepositionofthermosensitivechemotherapeutics.
alterthesafetyproleandmaybelesscontrollableortargetable
thanstandardHIFUwithoutcavitation.Cavitation detection
isavailableonsomeMRI-HIFUsystemsasasafetymeasure.
6,31
Acousticcavitationreferstotheforma-
8,31–33
ese mechanical eects
6,33
Twoformsofcav-
35–37
6,38–42
Cavitation
6,43,44
However, cavitationmay
8
8,34
Histotripsy
HIFU mechanical eects on their own can result in precise
ablativelesions.
cavitation,wherebyshortpulses(1–2ms)ofveryhigh-intensity
US(upto100MPa)andtheirresultantmechanicalbioeects,
likely combined with high temperatures, achieve focal tissue vaporization and destruction.
waytoevaluatetheutilityofhistotripsy-basedtissuedestruction for clinical applications, including tumor ablation and
thrombolysis.
Microstreaming
Microstreamingistheresultofstablecavitation,whichgeneratesrapidmovementofuidnearmicrobubblesdue to their
oscillatingmotion.8Microstreamingcanresultintheproductionofshear forcesthatcausecellmembranedisruptionand
resultingcelldamage.
microstreamingshearforcesmayfacilitateUS-enhanceddrug
orgenedelivery.
8,31,45
Histotripsyreferstoacontrolledformof
6,8,31,46–48
Eorts are under
8,31
Transientcellmembraneinjurydueto
8,49
Radiationforces
HIFUcancreateradiationforcesintissuesthatarethe result
ofabsorptionand reectionofUSwaveenergy.
associatedwithadditionaldestructivebioeects,includingcell
membrane deformation and microstreaming.
forcesoccurringalongthedirectionoftheUSbeam,delivered
viapulsedsonications,havebeenimplicatedas a mechanism
forHIFU-enhanceddrugdeliverytotumors.
31,50,51
6,52
31,49
eseare
Radiation
HIFU system technology
Imagingguidance during HIFU oncologic therapy is critical
forimmediatepretreatmentplanning,intraproceduraltargeting,andsafetymonitoring,andpostproceduralassessmentof
therapeuticeect.CurrentlyHIFUimagingguidanceiseither
US-guidedorMRI-guided,witheachmodalityhavingspecic
advantagesanddisadvantages.
Ultrasound guidance
Worldwide,mostHIFUtreatmentsarebeingperformedunder
USguidance.
6,53
US-guidedHIFUinvolvessuperimposingthe
eldofthediagnostic transducerandtheeldoftherapeutic
source.1AdvantagesofUSguidanceareitsrelativelylowcost
andavailability.6Limitationsincludeitsdependenceonindividualoperatorskillanddicultieswithsonographicdelineationofthetumorinrelationtosurroundinganatomyduring
ablation.DuringHIFU treatment,cloudsof gas bubbles will
be visible as a region of echogenicity.1Whilethis echogenicityprovidesgeneralinformationaboutablationlocation,itcan
alsoimpedetargetvisualization.Intraproceduraltemperatures
alsocannotbereadilymeasuredwithcurrentUSimagingtechniques.6Reliablyreproducingthesameimageandtargetingthe
same anatomic locationduring treatment with US guidance
canalso be challenging.6Asnoted by Tempanyetal.,eorts
toimproveUSoncologicimagingareongoing,includingthose
directedtowardsthedevelopmentof US-based thermometry,
USelastography,andothermethodsfordetectingtissuecoagulationduringHIFU.
6,54–56
MRI guidance
Advantagesof real-time MRI guidanceduringHIFUtherapy
are its intrinsic resolution, multiplanar imaging capabilities,
and the availability of intraprocedural temperature-sensitive
MRI parameters. T1-weighted, proton density, and
diusion-weightedimagingareall temperature-sensitiveand
havebeenstudiedasameansforguidingthermalablation.
emostwidelyusedmethodformonitoringMR-guidedthermal therapies is the proton resonance frequency(PRF) shi
method.
theexternallyappliedmagneticeldofMRI, thusdecreasing
theresonantfrequencyofprotons.Whenthetissuetemperaturerises,hydrogenbondingispartiallydisrupted,leadingto
increasedelectronshieldingofprotonsandareductioninresonantfrequency.iseecthasbeenshowntobethesamefor
allaqueoustissuesandlinearwithinthetemperaturerangeof
interest,withatemperaturecoecient,α= 0.01ppm/°C.Use
60
Normally, hydrogen electrons shield the protons from
6,57–59
23

Section II:Principles of image-guided therapies
−
0
∅∅
∅
0
of this relationshipto measure temperature is referred to as
PRFshithermometry.61Employingthismethod,tissuetemperaturechangesaredeterminedbythe changeinphaseofa
seriesofgradientechoimagesandaredenedbythefollowing
relationship:
T=
∆
∝γ
0
BTE
wherethe echo time TE, theeld strength B0,and the gyromagnetic ratio γ are known,∅ is the phase in the current
image, and
is the phase of a baseline imageat a known
temperature. e linearity and temperature dependence of
thePRFanditsnearindependenceoftissuetypehavemade
PRF-based phase-mapping methods the preferred choice for
currentclinicalapplications.57Moreover,thetemperaturesensitivityofthePRFshimethoddoesnotdependonthechange
intissuepropertiessustained duringthermalcoagulation.
62,63
DrawbacksofthePRFshi-basedthermometrymethodareits
sensitivitytomotionanditsinaccuratetemperaturemeasurementsinfattissues.
6
Additional advantages of MRI guidance during HIFU
are the ability to visualize the devascularized ablation zone
attheendofthetreatmentsessionviagadolinium-enhanced
sequences.Morerecentuseof3TMRIforMRI-guidedHIFU
therapyoerspotentialimprovementsintumormargindelineation compared with imaging at 1.5 T, given the increased
signal-to-noise ratio and imaging resolution at higher magneticeldstrengths.AdvancedMRI techniques used in conjunctionwithtumor-speciccontrastagentsmayalsoimprove
tumordelineation and MRI-guided HIFU treatment ecacy
in the future.6 Disadvantages of MRI-guided HIFU are the
requirementforanMRI-compatibleUStransducer,theassociatedcostandrelativecomplexityofanintegratedsystem,lack
ofwidespreadavailabilityforthesedevices,andthe increased
safetyissuesmandatedinthesettingofanMRIenvironment.
HIFU devices
HIFU devices may be categorized as extracorporeal, endocavitary,andinterstitial.Extracorporealsystemsonthemarket
include both MR-guidedand US-guided systems, with most
US-guidedsystemsinusebeingemployedinAsia.31Interstitial
HIFUdevicesindevelopmentemployHIFUapplicatorscapableof360°rotation.
8,64
esemaybeabletotreattumorsites
notreadilytreatedwithmostextracorporealandendocavitary
platforms, such as biliary, esophageal, and prostate malignancy(thelatterviaatransurethralapproach).
8,64
ereader
isencouragedtoconsulttworecentreviewsbyTempanyetal.
andZhou,eachofwhichincludesasummarytableofexisting
HIFUdevicesandcurrentoncologicapplications.
6,8
Adetailed
listofHIFU manufacturerscan also be foundathttp://www
.fusfoundation.org/the-technology/manufacturers.
65
TwointracavitaryHIFUdevicesarecurrentlyavailablefor
clinical use: the Ablatherm(EDAP TMS, Lyon,France) and
Sonablate 500 (SonaCareMedical, Charlotte, NC, previously
FocusSurgery,Indianapolis,IN).31BothsystemsareUS-guided
and employ water-cooled transrectal US transducers under
robotic control. Both have been used primarily in clinical
trialsforthetreatmentofprostatecancer,althoughtheyhave
thepotentialforadditionalapplicationsinthepelvis.
AblathermdeviceemploysanHIFUprobewithdualUStransducerselementsforimagingvs.treatment.eSonablate500
employsasinglewater-cooledtransrectalUSapplicatorwith
“split-beam”technology,allowingnear-simultaneousimaging
andtreatment.
31,67
ExtracorporealHIFUdevicespossessalongerfocallength
andgreaterworkingdepththanintracavitarydevicesandhave
been used for a wider range of clinical applications.In general,extracorporealUS-guideddeviceshavebeenmorepopularinAsia.31eModelJC HIFU system (HaifuTechnology,
Chongquing, China) has been used to treat several types
of cancer, including liver and renal cancer.
31,68
US-guided HIFU devices include the HIFU-2001 (Sumo
Corporation, Kowloon, Hong Kong), which has been used
since2001 totreatcancerpatientsinChina,HongKong,and
Korea, the HIFUNIT-9000 tumor therapy system (Shanghai
AishenTechnology,Shanghai,China)andtheFEP-BYTMsystem(YuandeBiomedicalEngineering,Beijing,China).31One
oftwocommerciallyavailableMRI-guidedHIFUextracorporeal devices is the ExAblate system (InSightec, Haifa, Israel),
which uses real-time thermometry under MRI guidance. It
is currently used worldwide to treat uterine broids and in
EuropeitisCE-approvedforthetreatmentofbonemetastases.
StudiesareongoinginEurope,Asia,andIsraelemployingthe
ExAblatesysteminthetreatmentofbreastcancerandadeno-
69,70
myosis.
emorerecentlydevelopedSonalleveMR-HIFU
(PhilipsHealthcare,Vantaa, Finland) employs a 256-element
phased-arrayextracorporealUStransducerintegratedintoan
MRItabletopthatiscompatiblewithPhilipsMRIplatforms.31
etransduceriselectronicallysteeredemployingavolumetric
ablationmethodologywherebycontinuousacoustic energy is
appliedinconcentriccirclesatthetargetfocus,takingadvan-
1,6
tageofheatdiusion14(Figure4.3).eSonallevesystemhas
receivedCEmarkingforthetreatmentofuterinebroidsand
FDAapprovalis currently being sought in the USA for this
application.e device has also received CE marking forthe
palliationof bone metastases andclinical trials forthe same
indication are under way in the USA. Additional oncologic
investigationswhichareongoingwiththisdeviceincludethe
treatmentofbreastandprostatecancer.
Extracorporealdevicesspecicallydesignedfortranscranial
HIFUincludetheExAblateNeuro hemisphericphased-array
HIFU system, which iscurrentlyused exclusively for neurosurgery research in the treatment of neuropathic pain and
movementdisorderssuchasParkinson’sdiseaseandessential
31,71
tremor.
particularlyinthetreatmentofessentialtremor.
Promisingearlyclinicalresultshavebeenobserved,
72
Clinical applications
US- and MRI-guided HIFUhavebeen utilized forthe treatment of a wide range of benign and malignant neoplasms.
Treatedmalignancies include cancersof the breast, prostate,
andliveraswellasboneandso-tissuemetastases.Smallclinical series have also described treatment of pancreatic and
renalcellcarcinomas.
58,73–76
Althougha detailed review ofall
31,66
e
Additional
24

Chapter4:High-intensity focused ultrasound
AB
Figure 4.3 Magnetic resonance-guided
high-intensity focused ultrasound (HIFU) volumetric
ablation. (A) Schematic of HIFU transducer
and beam, applying focused acoustic energy
in concentric circles within a treatment cell.
(B) Treatment cells 4 mm, 8 mm, or 12 mm in
diameter, with a ratio of cell diameter to length
4 mm
8 mm
Outwards-moving
concentric circles
4–12 mm
12 mm
of approximately 1:2.5. (Reprinted as per Elsevier
permissions requirements from Venkatesan AM,
Partanen A, Pulanic TK, et al. Magnetic resonance
imaging-guided volumetric ablation of symptomatic
leiomyomata: correlation of imaging with histology. J
Vasc Interv Radiol 2012; 23: 786–794.14)
pertinentliteratureconcerningoncologicapplicationsofHIFU
isbeyondthescopeofthischapter,thereaderisencouragedto
consultrecentreviewswhichfocusonthissubject.
2,56
Prostate
eimpetustodevelopHIFU forfocaltreatmentofprostate
cancerstemsfromthe risks associated with standard-of-care
prostatecancertherapies,whichmaybeincurredaerradical
prostatectomyaswellasaerexternal-beamradiation,brachytherapy,orhormonaltherapy.HIFUtreatmentofprostatecancerwasrstdescribedusingUSguidance,employingeitherthe
Sonablateor Ablathermsystemsinpatientsunder eitherspinalorgeneral anesthesia
6,76–79
Literaturereviewsindicatethat
US-guidedtransrectalHIFUhasbeenusedinatotalof3,018
publishedpatients,93%oftreatmentsforprimary-careprostate
cancer,and7%forsalvagetreatment.78Five-year(biochemical)
disease-freesurvivalratesarereportedas77%withuseofthe
Ablathermdeviceand45–84%withtheSonablatedevice,with
optimalratesofnegativebiopsyandlowprostate-specicantigenlevelassociatedwithlow-gradedisease.
80
Complications from US-guided transrectal HIFU include
urinary tract infection,stress incontinence, urinary retention,
bladder outlet obstruction, rectourethral stulae and, particularly in early studies, impotence.76 Recently, members of
theGastroenterologyand UrologyPaneloftheFDA’sMedical
Devices Advisory Committee voted against approval of the
Ablatherm-HIFU device for the treatment of low-risk, localizedprostatecancerintheUSA,citingconcernsregardingproof
ofsafetyandecacy.81Atpresent,analreviewofthedevice’s
pre-marketapprovalapplicationispendingbytheFDA,which
willundoubtedlyinuenceadoptionofthistreatmentmodality
inthe USA.Ablatherm-HIFUis approvedandcommercialized
inEuropeforthetreatmentofprostatecancer.
81
MRI-guided transrectal HIFU has been more recently
described,performedinconjunctionwithreal-time intraproceduralMRthermometryandimaging ofthetargetandvulnerableregionalanatomy,includingtheneurovascularbundle
and rectal wall.6 Earlyexperience by Napoli et al. described
thefeasibilityofMRI-guidedtransrectalHIFUpriortoradical
prostatectomyin5patientswithunifocalbiopsy-provenprostatecancerevidentonpreoperativemultiparametricimaging.3
Histopathology conrmed extensive coagulative necrosis,with no residual tumorin the ablated area.3MRI-guided
transurethral HIFU of the prostate is also being explored,
potentially oering an even greater safety prole.82 We and
othershavepursuedpreclinicalstudiesemployingMRI-guided
transurethralHIFUinacaninemodelforfocalprostateablation (Figures 4.4 and 4.5).
82,83
A clinical feasibility study by
Chopra et al. employed transurethral MRI-guided HIFU in
8 patientswith localizedprostatecancer(Gleasonscore≤ 7,
prostate-specicantigenlevel<15μg/L)priortoradicalprostatectomy.84isstudyconrmed thesafetyandfeasibilityof
this treatment,with a mean tissuetreatmentrateof0.5mL/
min,andspatialtargetingaccuracyof–1.0±2.6mm.
84
High-qualityevidence ontheecacyandsafetyofHIFU
in prostatecanceris still needed,asmost clinical studies to
date are clinical series lacking a control arm. Randomized
controlledtrialsofsucientsizecomparingHIFUwithconventionalsurgicalandnon-surgicaltreatmentortonotreatment (active surveillance) are necessary. Data on overall
survival,prostatecancer-specicsurvival,adverseevents,and
quality-of-lifemetricsarecritical.80Continuedclinicalexperienceandtechnical improvementsareanticipatedtoimprove
theaccuracyandecacyofHIFUtherapyforprostatecancer
inthefuture.
Breast
AdvantagesofutilizingHIFUinthebreastincludetargetproximitytothetransducer,presenceofaso-tissueacousticwindow,andtheabilitytoimmobilizethetargettissue.emain
argumentagainstnon-invasivebreastcancertherapies,includingHIFU,isthatmarginstatuscannotbeassessedduetolack
ofa pathologicalspecimen.TechnicalchallengesforHIFUin
thebreastincludetherisksofinjurytoskin,rib,andlungsand
the relative insensitivityof existing PRF-based thermometry
infattissues.31Technicaldevelopmentswhichmaysurmount
these challenges include device designs enabling focal point
correctionsinthesettingoftissueheterogeneity.
ere remains ongoing interest in breast HIFU as a
breast-conservingalternativetherapy(Figures4.6,4.7,and4.8).
Prior preclinical and clinical series suggest HIFU is feasible
andmaybeecaciousin the breast,althoughmoreresearch
in this areais needed andthe exact role for HIFU in breast
cancerisyettobewelldened.Gianfeliceetal.describedfeasibilityofMRI-guidedHIFUin24patientswithbiopsy-proven
breast cancer who refused surgery and underwent HIFU as
31,85,86
25

Section II:Principles of image-guided therapies
Figure 4.4 Planning and temperature
mapping for a focal prostate ablation using
magnetic resonance imaging-guided
ultrasound (US) therapy. (A, B) Prostate
was clearly identified on the T2-weighted
axial and sagittal planning images, and a
temperature feedback control point within
the prostate was prescribed (green circle).
The red overlay shows the position of
the US applicator, and the dashed yellow
lines depict the position of the imaging
slices ((A) shows the slice position in (B),
and (B) shows the slice position in (A).)
Depiction of applicator within the prostate
is meant to be illustrative. (C, D) Color-coded
temperature maps overlaid on dynamic
magnitude images during a sonication
(using four transducer elements), showing
typical temperature distribution at the end
of a 124-second sonication. Temperature
monitoring and control were achieved
in the target location with fast-field echo
(FFE)-echo planar imaging (EPI) sequence,
using the proton resonance frequency shift
(PRFS) method for temperature mapping,
and by using a binary temperature feedback
algorithm. (B) and (D) are the sagittal
image planes corresponding to (A) and (C),
respectively. (Reprinted with permission
from Partanen A, Yerram NK, Trivedi H, et al.
Magnetic resonance imaging (MRI)-guided
transurethral ultrasound therapy of the
prostate: a preclinical study with radiological
and pathological correlation using
customized MRI-based moulds. BJU Int 2013;
508–516.82)
an adjunct to tamoxifen therapy.87 Nineteen of 24 patients
(79%) had negative biopsy results aer either one or two
treatmentsessions.87Furusawaet al. treated 21 patientswith
biopsy-provenductalcarcinomawiththeExAblatedevice.One
recurrencewasobservedin21patientsoveramedianfollow-up
of14months.69Wuet al.treated22patientswithbreastcancerwhoreceivedchemotherapy,radiation,andtamoxifen,followingHIFU using the ModelJC HIFU system,with 5-year
disease-freesurvivalandrecurrence-freesurvivalratesof95%
and 89%, respectively.88 Subsequently, Wu et al. described
treatmentof23patientswith histologically conrmed breast
cancerwhounderwentHIFUoftheirtumorsandanintended
1.5–2-cm tumor-free margin followed by modied mastectomy1–2weeksaerHIFU.89Ablationzonesizessignicantly
largerthanthetargetedtumorswereachieved,withcomplete
necrosisofthetreatedregionsconrmedathistopathology.
89
Liver
EortsareunderwaytoutilizeHIFUforhepaticmalignancy,
particularly in patients with unresectable hepatocellular carcinoma (HCC) or surgical comorbidities (Figures 4.9 and
4.10).90OngoingHIFUtechnicalchallengesduringliverabla-
tionincluderespiratorymotion,dicultywithadequateenergy
delivery through or between ribs, and long treatment times
associatedwithlargetumors.
mentsincluderespiratorygatingandselectiveelementactivationtoenableintercostalablation.93Complicationsdescribed
asa result of HIFU liver tumorablationinclude ribfracture
31,91,92
Potentialtechnicaldevelop-
and necrosis, diaphragmatic rupture, biliary obstruction,
pleural eusion, pneumothorax,and stula formation.94 e
majorityofclinicalexperienceandresearchconcerningHIFU
fortreatmentoflivertumorshasdevelopedinAsia,wherethe
prevalenceofHCCremainshigh.31Ngetal.describedtheoutcomeof49patientswithunresectableHCCtreatedwithHIFU
using the JC HIFU system (Chongqing Haifu Technology,
Chongqing,China).95 Median size of thetreated tumors was
2.2 cm (range 0.9–8 cm). A primary technique eectiveness
rateof79.5%(39of49patients)wasobserved,withtumorsize
(≥3.0cm)beingthesignicantriskfactoraectingcomplete
ablation rate and Child–Pugh liver function grading being
the signicant prognosticfactor inuencing overall survival.
One- and 3-year overall survival rates of 87.7% and 62.4%,
respectively, were observed, leading the authors to conclude
that HIFU is an eective treatment modality with favorable
survival outcome.95 Combined treatment with transarterial
chemoembolization (TACE) and HIFU in the treatment of
HCC has also been described. Wuet al. treated 50 consecutivepatientswithstageIVaHCCrandomizedtoeitherTACE
aloneorHIFUusingtheModelJCHIFUsystem followedby
TACE4–6weekslater.96Treatedtumorswere4–14cmindiameter(mean10.5cm).PatientstreatedwithTACEandUSablationhad higher survivalratesthan those treated with TACE
alone(P=0.007,log-ranktest).96emediansurvivaltimewas
11.3 monthsin the TACE+HIFUgroupand4.0 months in
theTACE-onlygroup(P=0.004).e 6-monthsurvival rate
was80.4–85.4%intheTACE+HIFUgroupand13.2%inthe
26

Chapter4:High-intensity focused ultrasound
Figure 4.5 Imaging to histopathologic
correlation after transurethral
magnetic resonance imaging
(MRI)-guided high-intensity focused
ultrasound. Representative examples
of contrast-enhanced imaging
showing non-perfused regions (A),
diffusion-weighted imaging (DWI)
(b-value = 2000) showing restricted
diffusion in ablated regions (B),
CK-8-stained tissue showing areas of
non-viable tissue (C), and real-time
cumulative thermal dose estimates (D).
Ablated volumes on histology appear
slightly distorted compared with MRI
due to differences in tissue slice position
AB
and shrinkage secondary to formalin
fixation. (Reprinted with permission from
Partanen A, Yerram NK, Trivedi H, et al.
Magnetic resonance imaging (MRI)-guided
transurethral ultrasound therapy of
the prostate: a preclinical study with
radiological and pathological correlation
using customized MRI-based moulds. BJU
Int 2013; 508–516.82)
CD
Figure 4.6 A 45-year-old woman with
ductal cancer (T1 N0 M0) of the left breast. At
pretreatment planning (A), T2-weighted axial
image shows the nodule and its distance from
the pectoralis muscle (red dashed line), and
(B) T2-weighted axial image with fat saturation
shows high signal intensity of the pathologic
nodule. (Reprinted with permission from
Napoli A, Anzidei M, Ciolina F, et al. MR-guided
high-intensity focused ultrasound: current
A B
TACE-onlygroup(P=0.003),andthe1-yearsurvivalratewas
42.9%and0%,respectively.
96
US-guidedHIFUhasbeenemployedinthetreatmentofprimary bone tumors and MRI-guided HIFU for palliation of
status of an emerging technology. Cardiovasc
Interv Radiol 2013; 36: 1190–1203.3)
painfulbonemetastases.
Bone
ermalablationinboneisfacilitatedbyitsabsorptivecapacity,withapproximately30%oftheenergyneededforso-tissue
ablationbeingnecessaryforeectiveablationinbone.6Todate,
Chenetal.describedaprospectiveclinicaltrialemploying
theJCHIFUsystemtotreatpatientswithprimarybonemalignancies.97Atotalof80patientsweretreated,62withUS-guided
HIFUpluschemotherapy,and14patientstreatedwithHIFU
27

Section II:Principles of image-guided therapies
AB
CD
AB
Figure 4.7 Breast magnetic
resonance-guided focused ultrasound
surgery (MRgFUS) pretreatment imaging.
(A) Breast MRgFUS pretreatment evaluation
completed with MR spectroscopy.
(B) Dynamic gadolinium-enhanced
T1-weighted images for perfusion.
(C) Diffusion-weighted image for molecular
restriction. (D) Apparent diffusion coefficient
map. All are indicative of malignancy.
(Reprinted with permission from Napoli
A, Anzidei M, Ciolina F, et al. MR-guided
high-intensity focused ultrasound: current
status of an emerging technology. Cardiovasc
Interv Radiol 2013; 36: 1190–1203.3)
only. Complete tumor ablation delineated on follow-up CT,
MRI,andsingle-photonemissionCTimagingwasobservedin
69of80patients,with5of69 patients(7%) whounderwent
completeablation experiencing local recurrences during the
follow-upperiod.
97
Promisingresultshavebeendescribedforthe palliation
ofpainfulbonetumorswithHIFU.HIFUtreatmentgoalsfor
pain palliationdier from those needed to achieve tumor
ablation.ForHIFUbonepainpalliation,theUSfocalpoint
isintentionallyplacedbeyondthebonesurface,withthermal
energylocalizedtothe periostealbone–sotissueinterface
andpalliationattributedtodenervationofperiostealnerves.6
Liberman et al. reported results from a multicenter trial
employing the ExAblate MR thermometry-guided focused
US(MRgFUS)systemto evaluate thesafetyandecacyof
MRI-guidedHIFUinthepalliativetreatmentofbonemetastases.98irty-sixprocedureswereperformedon31patients,
with72%ofevaluablepatients(18/25)reportingsignicant
painimprovement,denedasareductionintheirvisualanalogscalescoreof>2points.Averagevisualanalogscalescore
reductionsfrom 5.9 priorto treatment to 1.8 at 3 months
posttreatment were observed. In all, 67% of patients with
Figure 4.8 Breast magnetic
resonance-guided focused ultrasound
surgery (MRgFUS) pre- and posttreatment
imaging. (A) Gadolinium-enhanced T1
gradient-echo fat-saturated axial image shows
the malignant highly vascular breast nodule
before MRgFUS. (B) After MRgFUS treatment,
no residual enhancement of ablated lesion is
detectable. (Reprinted with permission from
Napoli A, Anzidei M, Ciolina F, et al. MR-guided
high-intensity focused ultrasound: current
status of an emerging technology. Cardiovasc
Interv Radiol 2013; 36: 1190–1203.3)
28
Соседние файлы в папке Библиотека им академика М.И. Перельмана
